Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hypoxia × Atovaquone × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian High Grade Serous Adenocarcinoma 1 Medulloblastoma 1 Locally Advanced Non-Small Cell Lung Cancer 1 Leukemia, Myeloid, Acute 1 Hypoxia 1 Glioma 1 Diffuse Intrinsic Pontine Glioma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol 5 TH 302 4 pimonidazole 3 fluoroazomycin arabinoside 3 Radiotherapy 3 Propofol 3 Injections 3 pomalidomide 1 gadobutrol 1 fluoromisonidazole 1 fludarabine 1 Tirapazamine 1 Temozolomide 1 Sodium Chloride 1 Sevoflurane 1 Saline Solution 1 Pancreaticoduodenectomy 1 Oxygen 1 Nitroglycerin 1 Nimorazole 1 Magnetic Resonance Spectroscopy 1 Ketamine 1 Ipilimumab 1 Hydroxychloroquine 1 Gemcitabine 1 Furosemide 1 Ferrosoferric Oxide 1 Exercise 1 Ethiodized Oil 1 Diagnostic Imaging 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02628080 2019-09-04

ATOM

University of Oxford

Phase EARLY_PHASE1 Completed

Hypoxia, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡